Literature DB >> 21205443

The pharmacokinetics of enrofloxacin in adult African clawed frogs (Xenopus laevis).

Antwain M Howard1, Mark G Papich, Stephen A Felt, Charles T Long, Gabriel P McKeon, Emmitt S Bond, Stéphanie L Torreilles, Richard H Luong, Sherril L Green.   

Abstract

Pharmacokinetics of enrofloxacin, a fluoroquinolone antibiotic, was determined in adult female Xenopus laevis after single-dose administration (10 mg/kg) by intramuscular or subcutaneous injection. Frogs were evaluated at various time points until 8 h after injection. Plasma was analyzed for antibiotic concentration levels by HPLC. We computed pharmacokinetic parameters by using noncompartmental analysis of the pooled concentrations (naive pooled samples). After intramuscular administration of enrofloxacin, the half-life was 5.32 h, concentration maximum was 10.85 μg/mL, distribution volume was 841.96 mL/kg, and area under the time-concentration curve was 57.59 μg×h/mL; after subcutaneous administration these parameters were 4.08 h, 9.76 μg/mL, 915.85 mL/kg, and 47.42 μg×h/mL, respectively. According to plasma pharmacokinetics, Xenopus seem to metabolize enrofloxacin in a manner similar to mammals: low levels of the enrofloxacin metabolite, ciprofloxacin, were detected in the frogs' habitat water and plasma. At necropsy, there were no gross or histologic signs of toxicity after single-dose administration; toxicity was not evaluated for repeated dosing. The plasma concentrations reached levels considered effective against common aquatic pathogens and suggest that a single, once-daily dose would be a reasonable regimen to consider when treating sick frogs. The treatment of sick frogs should be based on specific microbiologic identification of the pathogen and on antibiotic susceptibility testing.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21205443      PMCID: PMC2994045     

Source DB:  PubMed          Journal:  J Am Assoc Lab Anim Sci        ISSN: 1559-6109            Impact factor:   1.232


  21 in total

1.  Allometric analysis of ciprofloxacin and enrofloxacin pharmacokinetics across species.

Authors:  S K Cox; M B Cottrell; L Smith; M G Papich; D L Frazier; J Bartges
Journal:  J Vet Pharmacol Ther       Date:  2004-06       Impact factor: 1.786

Review 2.  Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections.

Authors:  E Nuermberger; J Grosset
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-13       Impact factor: 3.267

3.  Standardization of a broth microdilution susceptibility testing method to determine minimum inhibitory concentrations of aquatic bacteria.

Authors:  R A Miller; R D Walker; J Carson; M Coles; R Coyne; I Dalsgaard; C Gieseker; H M Hsu; J J Mathers; M Papapetropoulou; B Petty; C Teitzel; R Reimschuessel
Journal:  Dis Aquat Organ       Date:  2005-05-20       Impact factor: 1.802

4.  Disease attributed to Mycobacterium chelonae in South African clawed frogs (Xenopus laevis).

Authors:  S L Green; B D Lifland; D M Bouley; B A Brown; R J Wallace; J E Ferrell
Journal:  Comp Med       Date:  2000-12       Impact factor: 0.982

5.  Identification and management of an outbreak of Flavobacterium meningosepticum infection in a colony of South African clawed frogs (Xenopus laevis).

Authors:  S L Green; D M Bouley; R J Tolwani; K S Waggie; B D Lifland; G M Otto; J E Ferrell
Journal:  J Am Vet Med Assoc       Date:  1999-06-15       Impact factor: 1.936

6.  In vitro pharmacodynamic modelling simulating free serum concentrations of fluoroquinolones against multidrug-resistant Streptococcus pneumoniae.

Authors:  G G Zhanel; M Walters; N Laing; D J Hoban
Journal:  J Antimicrob Chemother       Date:  2001-04       Impact factor: 5.790

7.  Pharmacokinetics after intravenous and oral administration of enrofloxacin in sheep.

Authors:  Eden C Bermingham; Mark G Papich
Journal:  Am J Vet Res       Date:  2002-07       Impact factor: 1.156

8.  Identification and developmental expression of Xenopus laevis SUMO proteases.

Authors:  Yonggang Wang; Debaditya Mukhopadhyay; Smita Mathew; Takashi Hasebe; Rachel A Heimeier; Yoshiaki Azuma; Nagamalleswari Kolli; Yun-Bo Shi; Keith D Wilkinson; Mary Dasso
Journal:  PLoS One       Date:  2009-12-24       Impact factor: 3.240

9.  EYA1 mutations associated with the branchio-oto-renal syndrome result in defective otic development in Xenopus laevis.

Authors:  Youe Li; Jose M Manaligod; Daniel L Weeks
Journal:  Biol Cell       Date:  2010-02-17       Impact factor: 4.458

10.  The F-box protein Cdc4/Fbxw7 is a novel regulator of neural crest development in Xenopus laevis.

Authors:  Alexandra D Almeida; Helen M Wise; Christopher J Hindley; Michael K Slevin; Rebecca S Hartley; Anna Philpott
Journal:  Neural Dev       Date:  2010-01-04       Impact factor: 3.842

View more
  3 in total

1.  Tissue distribution of enrofloxacin in African clawed frogs (Xenopus laevis) after intramuscular and subcutaneous administration.

Authors:  Stephen Felt; Mark G Papich; Antwain Howard; Tyler Long; Gabriel McKeon; Stéphanie Torreilles; Sherril Green
Journal:  J Am Assoc Lab Anim Sci       Date:  2013-03       Impact factor: 1.232

2.  Efficacy of enrofloxacin in a mouse model of sepsis.

Authors:  Andrea R Slate; Sheila Bandyopadhyay; Kevin P Francis; Mark G Papich; Brian Karolewski; Eldad A Hod; Kevin A Prestia
Journal:  J Am Assoc Lab Anim Sci       Date:  2014-07       Impact factor: 1.232

Review 3.  Aquatic Freshwater Vertebrate Models of Epilepsy Pathology: Past Discoveries and Future Directions for Therapeutic Discovery.

Authors:  Rachel E Williams; Karen Mruk
Journal:  Int J Mol Sci       Date:  2022-08-03       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.